Your browser doesn't support javascript.
loading
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
Xu, Nanwei; Zhao, Jinge; Zhao, Fengnian; Liu, Haoyang; Yin, Wenlian; Zhu, Sha; Nie, Ling; Sun, Guangxi; Zheng, Linmao; Liu, Zhenhua; Cai, Diming; Chen, Junru; Dai, Jindong; Ni, Yuchao; Wang, Zhipeng; Zhang, Xingming; Liang, Jiayu; Chen, Yuntian; Hu, Xu; Pan, Xiuyi; Yin, Xiaoxue; Zhu, Xudong; Zhang, Yaowen; Wang, Zilin; Zeng, Yuhao; Wang, Minghao; Shen, Pengfei; Chen, Ni; Zeng, Hao.
Afiliación
  • Xu N; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhao J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. jingezhao@foxmail.com.
  • Zhao F; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liu H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Yin W; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhu S; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Nie L; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Sun G; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zheng L; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liu Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Cai D; Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Chen J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Dai J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Ni Y; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Wang Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhang X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liang J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Chen Y; Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Hu X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Pan X; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Yin X; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhu X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhang Y; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Wang Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zeng Y; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Wang M; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Shen P; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. cdhx510@163.com.
  • Chen N; Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China. chenni1@163.com.
  • Zeng H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. kucaizeng@163.com.
J Cancer Res Clin Oncol ; 149(10): 7247-7258, 2023 Aug.
Article en En | MEDLINE | ID: mdl-36907910
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article